country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-188159

Copy Link Print Information

BMK-Y101

BMK-Y101 is a potent CDK kinase inhibitor. BMK-Y101 induces tumor cell apoptosis by inhibiting CDK kinases. BMK-Y101 can be used for research on hepatocellular carcinoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1314096-69-9
Formel: C₁₂H₁₄BrN₅O₅
Molecular Weight:388.17

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

BMK-Y101 Chemical Structure

CAS. Nr.: 1314096-69-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

BMK-Y101 is a potent CDK kinase inhibitor. BMK-Y101 induces tumor cell apoptosis by inhibiting CDK kinases. BMK-Y101 can be used for research on hepatocellular carcinoma^[1]^[2]^[3].

IC₅₀ & Target

^[1]^[3]

CDK7

CDK9

CDK1

CDK2

Alle CDK Isoform-spezifische Produkte anzeigen :

In Vitro

BMK-Y101 induces apoptosis in hepatocellular carcinoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMK-Y101 exhibits antitumor growth activity in hepatocellular carcinoma xenograft mouse models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

CAS. Nr. 1314096-69-9
Molecular Weight 388.17
Formel C₁₂H₁₄BrN₅O₅
SMILES

O[C@H]1[C@H](O)[C@H](O[C@H]1CO)N2C=NC(N)=C3C2=NC(Br)=C3C(N)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. KIM Y J, et al. Selectivity between N-1 and N-7 nucleosides: regioselective synthesis of BMK-Y101, a potent cdk7 and 9 inhibitor. Tetrahedron Letters, 2013, 54(41): 5484-5488.

[2]. GANBOLD E O, et al. Raman spectroscopy and density functional theory study of energetically closely separated C2′‐endo and C3′‐endo pentose forms in purine nucleoside analogue drug‐gold conjugates. Journal of Raman Spectroscopy, 2018, 49(3): 424-430.

[3]. PERLÍKOVÁ P, et al. Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides [J]. MedChemComm, 2017, 8(12): 2213-2226.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen